PIŚMIENNICTWO
1. Antimicrobial stewardship definition and core principles. American Veterinary Medical Association website. avma.org/KB/Policies/Pages/Antimicrobial-Stewardship-Definition-and-Core-Principles.aspx. Accessed January 3, 2019.
2. Teale CJ, Moulin G. Prudent use guidelines: a review of existing veterinary guidelines. Rev Sci Tech 2012;31(1):343-354.
3. Knights CB, Mateus A, Baines SJ. Current British veterinary attitudes to the use of perioperative antimicrobials in small animal surgery. Vet Rec 2012;170(25):646.
4. Bisson JL, Argyle DJ, Argyle SA. Antibiotic prophylaxis in veterinary cancer chemotherapy: a review and recommendations. Vet Comp Oncol 2018;16(3):301-310.
5. Veterinary Cooperative Oncology Group – common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.1. Vet Comp Oncol 2016;14(4):417-446.
6. Vail DM. Supporting the veterinary cancer patient on chemotherapy: neutropenia and gastrointestinal toxicity. Top Companion Anim Med 2009;24(3):122-129.
7. Britton BM, Kelleher ME, Gregor TP, et al. Evaluation of factors associated with prolonged hospital stay and outcome of febrile neutropenic patients receiving chemotherapy: 70 cases (1997-2010). Vet Comp Oncol 2014;12(4):266-276.
8. Lo N, Cullen M. Antibiotic prophylaxis in chemotherapy-induced neutropenia: time to reconsider. Hematol Oncol 2006;24(3):120-125.
9. Chrischilles EA, Link BK, Scott SD, et al. Factors associated with early termination of CHOP therapy and the impact on survival among patients with chemosensitive intermediate-grade non-Hodgkin’s lymphoma. Cancer Control 2003;10(5):396-403.
10. Teillant A, Gandra S, Barter D, et al. Potential burden of antibiotic resistance on surgery and cancer chemotherapy antibiotic prophylaxis in the USA: a literature review and modeling study. Lancet Infect Dis 2015;15(12):1429-1437.
11. Gustafsson I, Sjolund M, Torell E, et al. Bacteria with increased mutation frequency and antibiotic resistance are enriched in the commensal flora of patients with high antibiotic usage. J Antimicrob Chemother 2003;52(4):645-650.
12. Taur Y, Pamer EG. The intestinal microbiota and susceptibility to infection in immunocompromised patients. Curr Opin Infect Dis 2013;26(4):332-337.
13. Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000;18(16):3038-3051.
14. Sorenmo KU, Harwood LP, King LG, et al. Case-control study to evaluate risk factors for the development of sepsis (neutropenia and fever) in dogs receiving chemotherapy. J Am Vet Med Assoc 2010;236(6):650-656.
15. Mealey KL, Fidel J, Gay JM, et al. ABCB1-1Delta polymorphism can predict hematologic toxicity in dogs treated with vincristine. J Vet Intern Med 2008;22(4):996-1000.
16. Mealey KL, Meurs KM. Breed distribution of the ABCB1-1Delta (multidrug sensitivity) polymorphism among dogs undergoing ABCB1 genotyping. J Am Vet Med Assoc 2008;233(6):921-924.
17. Thamm DH, Vail DM. Aftershocks of cancer chemotherapy: managing adverse effects. J Am Anim Hosp Assoc 2007;43(1):1-7.
18. Boudreaux B. Antimicrobial use in the veterinary cancer patient. Vet Clin North Am Small Anim Pract 2014;44(5):883-891.
19. Pugh R, Grant C, Cooke RP. Short-course versus prolonged-course antibiotic therapy for hospital-acquired pneumonia in critically ill adults. Cochrane Database Syst Rev 2015;(8):CD007577.
20. Chotiprasitsakul D, Han JH, Cosgrove SE, et al. Antibacterial Resistance Leadership Group. Comparing the outcomes of adults with Enterobacteriaceae bacteremia receiving short-course versus prolonged-course antibiotic therapy in a multicenter, propensity score-matched cohort. Clin Infect Dis 2017;66(2):172-177.
21. Weese JS, Giguere S, Guardabassi L, et al. ACVIM consensus statement on therapeutic antimicrobial use in animals and antimicrobial resistance. J Vet Intern Med 2015;29(2):487-498.
22. Vidal L, Ben Dor I, Paul M, et al. Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients. Cochrane Database Syst Rev 2013;(10):CD003992.
23. World Health Organization. Critically Important Antimicrobials for Human Medicine. 5th rev. Geneva, Switzerland: WHO; 2016. who.int/iris/bitstream/handle/10665/255027/9789241512220-eng.pdf;jsessionid=C3D20B7F35E2DECB212B1E3357B0887B?sequence=1. Accessed June 23, 2019.
24. Cruciani M, Malena M, Bosco O, et al. Reappraisal with meta-analysis of the addition of gram-positive prophylaxis to fluoroquinolone in neutropenic patients. J Clin Oncol 2003;21(22):4127-4137.
25. Skoetz N, Bohlius J, Engert A, et al. Prophylactic antibiotics or G(M)-CSF for the prevention of infections and improvement of survival in cancer patients receiving myelotoxic chemotherapy. Cochrane Database Syst Rev 2015;(12):CD007107.
